Suffwan Eltom’s Post

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/g7MWSBE8 #UNGA79 #ForKidneyHealth https://lnkd.in/gjw8i25E

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/eXFe-UJf #UNGA79 #ForKidneyHealth https://lnkd.in/ePHbvkvt

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/egvUZA4y #UNGA79 #ForKidneyHealth https://lnkd.in/eNi6DBQZ

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/ewpy5TCe #UNGA79 #ForKidneyHealth https://lnkd.in/e5SV4RHt

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health, and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/ebqVuN_6 #UNGA79 #ForKidneyHealth https://lnkd.in/eTp3RBuA

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/gi5SZkUt #UNGA79 #ForKidneyHealth https://lnkd.in/gXsnmQEu

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/eG25KY8E #UNGA79 #ForKidneyHealth https://lnkd.in/eM2yBFFp

Early treatment of chronic kidney disease (CKD) can slow or halt its progression, improve quality of life, and reduce cardiovascular risk. Sadly, 90% of patients with CKD are undiagnosed. During UNGA79, AstraZeneca — together with co-sponsor Boehringer Ingelheim and partners the International Society of Nephrology Global Patient Alliance for Kidney Health and co-host Devex — convened leading voices in global health and policy for a critical discussion on the urgent need to implement patient-centred and evidence-based policies to enable earlier detection and diagnosis of CKD and immediate access to care and recommended treatments. We need to act now. Sign up to be part of making the change: https://lnkd.in/e6FPqg4t #UNGA79 #ForKidneyHealth https://lnkd.in/eJGTj8Yy

Hypertrophic cardiomyopathy (HCM) emerged as a distinct disease about 60 years ago, yet the condition is still often underdiagnosed and inconsistently managed, leading to delayed treatment, increased risk of complications and preventable morbidity. While rare, HCM is the most common inherited heart disease, and it is estimated that 1 in 500 people are living with HCM and are unaware. The American Heart Association is thrilled to announce a groundbreaking $8M Hypertrophic Cardiomyopathy Registry, Recognition, and Site Certification Initiative to establish a comprehensive HCM system of care, anchored in evidence-based measures and quality thresholds. This three-year initiative aims to improve patient outcomes and care by standardizing the assessment, referral and treatment of patients with HCM. We extend our sincere gratitude to founding sponsor Bristol Myers Squibb for their support in helping translate science into practice. Learn more about this new initiative at http://spr.ly/6046spyvQ. #HCM #AHA24

Straight off the back of European Renal Association (ERA) Congress, where our AstraZeneca team presented new evidence to support early diagnosis and immediate access to treatment and care for chronic kidney disease (CKD), we are here at the #WHA77 supporting International Society of Nephrology and Global Patient Alliance for Kidney Health events advocating for change. New modelling data and real-world evidence from the UK, Spain, Germany, and the Netherlands predict that timely diagnosis and guideline-directed medical therapy in patients at high risk of CKD would improve patient outcomes, greatly reducing the economic burden associated with managing cardiovascular events. Discover more about how we can make the change #ForKidneyHealth: https://lnkd.in/es-eJaHj